Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.08.15

Sai Life Sciences opens new, state-of-the-art Research & Technology Centre in Hyderabad

• Completes first phase in committed investment of US$ 150M (> INR 1000 Cr)
• Sri KT Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government of Telangana inaugurates the facility

Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the inauguration of its new Research and Technology (R&T) Centre in Hyderabad, India. Sri K T Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government of Telangana formally inaugurated the facility in the presence of other dignitaries.

Speaking on the occasion, Sri KT Rama Rao said, “I’m very happy that the esteemed leadership of Sai Life sciences has considered Telangana for setting up their new R&D centre. Life Sciences is one of the key focus sectors for the Government of Telangana. Hyderabad serves more than 1000 global innovators in their vision to develop innovative and affordable medicines for the world. I sincerely congratulate the entire team of Sai Life Sciences, not only for the new Research & Technology Centre but, also for their work towards the development and manufacturing of new life saving medicines.”

Built with an aspiration to achieve the best global benchmarks in lab infrastructure, the new R&T facility has several unique aspects such as intelligent & ergonomic lab design to enhance safety and productivity, advanced automation for seamless data capture during process development, lean & 5S approach to enhance productivity and collaborative workspaces for engendering innovation.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said, “Our philosophy behind building this new facility was to go beyond what the norm is in India and to create what our global innovator partners expect in their inhouse capabilities.” He further added, “We are an example of what is possible in Hyderabad’s rich life sciences ecosystem. Today, as we build world class R&D capabilities and invest in nurturing talent with deep domain expertise, I can unhesitatingly say, Hyderabad is truly a city where pharma dreams are made.”

The new 83,000 sq.ft. (7700 sq.m.) facility houses state-of-the-art research capabilities and advanced technology platforms, augmenting the company’s capabilities in providing superior scientific solutions to its pharma and biotech innovator customers globally. It has 24 chemistry labs with 250 fume hoods, analytical labs, fully equipped technology suite and a dedicated process safety lab.

Sai Life Sciences began a process of organizational transformation in 2019 reinventing itself as a new generation global CDMO. Through this initiative, named Sai Nxt, the company is investing over US$ 150M (> INR 1000 Cr) to expand and upgrade its R&D and manufacturing facilities, induct top-notch global scientific and leadership talent, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

Watch the full event video below:

Share article

More News

2024.10.28

Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India. The General Good Manufacturing Practices (GMP) audit was conducted at the […]
Read more

2024.10.07

Sai Life Sciences releases Sustainability Report 2024

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], published its Sustainability Report for 2023-2024. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, this fifth edition of the Sustainability Report is based on the theme, ‘Synergising Sustainability, Performance and Growth.’ The full report can be read here. Making […]
Read more

2024.08.09

Sai Life Sciences elevates Compound Management process with in-house software application, CORAL

Compound management is a vital function in pharmaceutical research. A streamlined environment can bring significant value to the process in the form of productivity and efficiency. Recognizing the importance of this function, we have made our Compound Management suite for Discovery services smarter with the introduction of an in-house software application, Compound Organization and Registration […]
Read more

2024.07.29

Sai Life Sciences inducts 96 trainees across campuses in India

“I just got my first pair of safety shoes and I’m thrilled! Exploring the facility for the first time is such a joy!” – Spurthi R, Trainee, Medicinal Chemistry, Shamirpet. Ushering in a season of new beginnings, we welcomed 96 trainees across our campuses in India. These young individuals have been selected from eight colleges […]
Read more

2024.02.08

Sai Life Sciences releases its Sustainability Report 2023

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), released its Sustainability Report 2022-2023. Developed in accordance with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, the fourth edition of the Sustainability report is based on the theme ‘Steadfast on Sustainability,’ and it articulates the company’s commitment to sustainability […]
Read more